Table 1:

HSP27 Immunotherapy and the Divergent Regulation of LDLR and PCSK9 Expression

	LDLR	PCSK9
Hepatic (in vivo): rHSP25 vaccination
• mRNA	Increase in LDLR mRNA (qPCR; Fig. 4C)	No change in mRNA (Suppl. Fig. IIIA)
• protein	Increased protein (Western blot; Fig. 4D,4E)	No change in hepatic protein levels (Suppl. Fig. IIIB,IIIC) but reduced plasma levels in male but not female mice (Fig. 4B)
• transcriptional regulation	No change in upstream in upstream transcriptional factors SREBP2 & HNF1-α (Suppl. Fig. IIID, IIIE)	No change in upstream in upstream transcriptional factors SREBP2 & HNF1-α (Suppl. Fig. IIID, IIIE)
HepG2 Hepatocytes (in vitro): [rHSP27 + PAb] treatment	LDLR	PCSK9
• mRNA	Increased mRNA (qPCR; Fig. 5B)	Minor, transient decrease in mRNA (qPCR; Suppl Fig. VA)
• protein	Increased protein (SILAC; Fig. 5A)	Decreased protein (SILAC; Fig. 5A)
• dependence on intracellular cholesterol	Increased expression is independent of intracellular cholesterol (Fig. 5C)	Decreased expression is independent of intracellular cholesterol (Fig. 5C)
• dependence on NF-κB activation	Decreased expression with NF-kB blockade (Fig. 6B–6D)	No change in expression with NF-kB blockade (Suppl. Fig. VF)